Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 6, 2007, Pages 899-905

  Patel, Jyoti B ^a,b   Khandelwal, Aakanksha ^a   Chopra, Pankaj ^a,c   Handratta, Venkatesh D ^a,d   Njar, Vincent C O ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c University of Missouri   (United States)

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Anti cancer agents; Pharmacokinetics; Retinoic acid metabolism blocking agents; Retinoids; Toxicology

Indexed keywords

ANTINEOPLASTIC AGENT; RETINOIC ACID; UNCLASSIFIED DRUG; VN 14 1; VN 2 1; VN 50 1; VN 66 1; VN 67 1; VN 69 1;

ALOPECIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SYNTHESIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SKIN APPENDAGE DISEASE; WEIGHT REDUCTION;

ALOPECIA; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BODY WEIGHT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; IMIDAZOLES; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED BALB C; SKIN DISEASES; TISSUE DISTRIBUTION; TRETINOIN;

EID: 34548389461     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0438-3     Document Type: Article

References (29)

1. Adams J (1993) Structure-activity and dose-response relationships in the neural and behavioral teratogenesis of retinoids. Neurotoxicol Teratol 15:193-202
2. Altucci L, Gronemeyer H (2001) The promise of retinoids to fight against cancer. Nat Rev Cancer 1:181-193
3. Belosay A, Njar VCO, Brodie AMH (2006) Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole insensitive breast cancer cells. Cancer Res 66:11489-11493
4. Bollag W (1975) Therapy of epithelial tumors with aromatic retinoic acid analog. Chemotherapy 21:236-247
5. Boyle JO (2001) Retinoids mechanisms and cyclins. Curr Oncol Rep 3:301-305
6. Cohen M (1993) Terinoin: a review of preclinical toxicological studies. Drug Dev Res 30:244-251
7. Dragnev KH, Rigas JR, Dmitrovsky E (2000) The retinoids and cancer prevention mechanisms. Oncologist 5:361-368
8. Fontana JA, Rishi AK (2002) Classical and novel retinoids: their targets in cancer therapy. Leukemia 16:463-472
9. Freemantle S, Spinella MJ, Dmitrovsky E (2003) Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 22:7305-7315
10. Herr RJ (2002) 5-Substituted-1H-tetrazoles as carboxylic acid isosteres: medicinal chemistry and synthetic methods. Bioorg Med Chem 10:3379-3393
11. Huynh CK, Brodie AM, Njar VCO (2006) Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice. Br J Cancer 94:513-523
12. Lindamood III C, Giles HD, Hill DL (1987) Preliminary toxicology profile of arotinoids SMR-2 and SMR-6 in male B6D2F1 mice. Fundam Appl Toxicol 8:517-530
13. Lindamood III C, Cope FO, Dillehay DL, Everson MP, Giles HD, Lamon EW, McCarthy DJ, Sartin JL, Hill DL (1990) Pharmacological and toxicological properties of carotinoids SMR-2 and SMR-6 in mice. Fundam Appl Toxicol 14:15-29
14. Le Doze F, Debruyne D, Albessard F, Barre L, Defer GL (2000) Pharmacokinetics of all-trans retinoic acid, 13-cis retinoic acid, and fenretinide in plasma and brain of rat. Drug Metab Dispos 28:205-208
15. Miller W (1998) The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Cancer 83:1471-1482
16. Njar VCO, Nnane IP, Brodie AM (2000) Potent inhibitors of retinoic acid metabolism enzyme(s) by novel azolyl retinoids. Bioorg Med Chem Lett 10:1905-1908
17. Njar VCO (2002) Cytochrome p450 retinoic acid 4-hyroxylase inhibitors: potential agents for cancer therapy. Mini Rev Med Chem 2:261-269
18. Njar VCO, Gediya L, Purushottamachar P, Chopra P, Vasaitis TS, Khandelwal A, Mehta J, Huynh C, Belosay A, Patel J (2006) Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatologic diseases. Bioorg Med Chem 14:4323-4340
19. Patel J B, Huynh CK, Handratta VD, Gediya LK, Brodie AM, Goloubeva OG, Clement OO, Nnane IP, Soprano DR, Njar VCO (2004) Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice. J Med Chem 47:6716-6729
20. Patel JB, Mehta J, Belosay A, Sabins G, Khandelwal A, Brodie AMH, Njar VCO (2006) Novel retinoic acid metabolism blocking agents (RAMBAs) have potent inhibitory activities on human breast cancer cells and tumor growth. In review
21. Staab HA (1962) Syntheses using heterocyclic amides (azolides). Angew Chem Internat Edit 1:351-367
22. Ulukaya E, Wood E (1999) Fenretinide and its relation to cancer. Cancer Treat Rev 25:229-235
23. Vaezi MF, Alam M, Sani BP, Rogers TS, Simpson-Herren L, Wille JJ, Hill DL, Doran TI, Brouillette WJ, Muccio DD (1994) A conformationally defined 6-s-trans-retinoic acid isomer: synthesis, chemopreventive activity, and toxicology. J Med Chem 37:4499-4507
24. Van Heusden J, Borgerus M, Ramaekers F, Xhonneux B, Wouters W, De Coster R, Smets G (1996) Liarozole potentiates the all-trans-retinoic acid induced structural remodeling in human breast carcinoma MCF-7 cells in vitro. Eur J Cell Biol 71:89-98
25. Van Huesden J, Van Ginckel R, Bruwiere H, Moelans P, Janssen B, Floren W, Leede BJ, Van Dun J, Sanz G, Venet M, Dillen L, Van Hove C, Willemsens G, Janicot M, Wouters W (2002) Inhibition of all-trans-retinoic acid metabolism by R116010 induces antitumor activity. Br J Cancer 86:605-611
26. Vasudevan J, Johnson AT, Huang D, Chandraratna RA. Compounds having activity as inhibitors of cytochrome P450A1. US Patent. 6,252,090. Other patents assigned to Allergan Sales Inc., include, US Patents 6,303,785 B1; 6,359,135 B1; 6,369,261 B1; 6,380,256 B1; 6,387,892 B1; 6,387,951 B1; 6,399,774 B1; 6,495,552 B2 and 531,599 B2
27. William JB, Napoli JL (1986) Inhibition of retinoic acid metabolism by imidazole antimycotics in F9 embryonal carcinoma cells. Biochem Pharmacol 36:1386-1388
28. Wouters W, Van Dun J, Dillen A, Coene M-C, Cools W, DeCoster R (1992) Effects of liarozole, a new antitumoral compound, on retinoic acid-induced inhibition of cell growth and on retinoic acid metabolism in MCF-7 human breast cancer cells. Cancer Res 52:2841-2846
29. Wu C, Njar V, Brodie A, Borenstein M, Nnane I (2004) Quantification of a novel retinoic acid metabolism inhibitor, 4-(1H-imidazol-1-yl)retinoic acid (VN/14-1RA) and other retinoids in rat plasma by liquid chromatography with diode-array detection. J Chromato B Analyt Technol Biomed Life Sci 810:203-208